Business

Mass. Movers

Biogen raises forecast as MS drug takes off

George Scangos heads Biogen Idec, whose shares are up 74 percent this year.

Globe file photo/2013

George Scangos heads Biogen Idec, whose shares are up 74 percent this year.

Advertisement

Biogen Idec Inc., maker of the multiple sclerosis drugs Avonex, Tysabri, and Tecfidera, boosted its 2013 forecast after Tecfidera sales topped estimates. Revenue this year will grow 23 to 25 percent, with adjusted earnings of $8.65 to $8.85 a share. It had projected revenue gaining 22 to 23 percent and earnings of $8.25 to $8.50. Quarterly Tecfidera sales of $286.4 million beat analysts’ average $217.2 million estimate. ‘‘Tecfidera crushed it,’’ wrote Mark Schoenebaum, at ISI Group. ‘‘This is really, truly, incredible.’’ Revenue rose 32 percent to $1.83 billion. Net income increased 22 percent to $487.6 million.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com